natgillin/translations-raw huggingface dataset:
The recommended dose of Fabrazyme for children and adolescents 8 – 16 years is 1 mg/kg body weight, once every 2 weeks.
Preporučena doza lijeka Fabrazyme za djecu i adolescente u dobi od 8 do 16 godina je 1 mg/kg tjelesne težine jedanput svaka 2 tjedna.
The recommended dose of Fabrazyme for children and adolescents 8 – 16 years is 1 mg/kg body weight, once every 2 weeks.
Preporučena doza lijeka Fabrazyme za djecu i adolescente u dobi od 8 do 16 godina je 1 mg/kg tjelesne težine, jedanput svaka 2 tjedna.
The recommended dose of filgrastim for PBPC mobilisation when used alone is 1.0 MU/kg/day (10 micrograms/kg/day) for 5-7 consecutive days.
Preporučena doza filgrastima za mobilizaciju stanica preteča periferne krvi kad se primjenjuje sam iznosi 1,0 MU/kg/dan (10 mikrograma/kg/dan) tijekom 5 do 7 uzastopnih dana.
The recommended dose of filgrastim is 0.5 MIU (5 μg)/kg/day.
Preporučena doza filgrastima je 0,5 MIU (5 μg) /dan.
The recommended dose of filgrastim is 0.5 MU (5 micrograms)/kg/day.
Preporučena doza filgrastima je 0,5 MU (5 mikrograma)/kg/dan.
The recommended dose of filgrastim is 0.5 MU/kg/day (5 μg/kg/day).
Preporučena doza filgrastima je 0,5 MU/kg na dan (5 μg/kg na dan).
The recommended dose of Firazyr is one injection (3 ml, 30 mg) applied subcutaneously (under the skin) as soon as you notice the attack of hereditary angioedema (for example increased skin swelling, particularly affecting the face and neck, or increasing tummy pain).
Preporučena doza Firazyra je jedna injekcija (3 ml, 30 mg) koja se primjenjuje supkutano (pod kožu) čim primijetite napadaj nasljednog angioedema (na primjer, povećano oticanje kože, osobito na licu i vratu ili sve jača bol u trbuhu).
The recommended dose of fondaparinux is 2.5 mg once daily administered by subcutaneous injection.
Preporučena doza fondaparinuksa je 2,5 mg jedanput na dan, primijenjeno supkutanom injekcijom.
The recommended dose of fondaparinux is 2.5 mg once daily.
Preporučena doza fondaparinuksa je 2,5 mg jedanput na dan.
The recommended dose of fondaparinux is 7.5 mg (patients with body weight  50,  100kg) once daily administered by subcutaneous injection.
Preporučena doza fondaparinuksa je 7,5 mg (za bolesnike tjelesne težine 50 i 100 kg) jedanput na dan, primijenjeno supkutanom injekcijom.
The recommended dose of FORSTEO is 20 micrograms administered once daily.
Preporučena doza lijeka FORSTEO iznosi 20 mikrograma jedanput na dan.
The recommended dose of Fortacin is 3 sprays (3 sprays = 1 dose) on the head of the penis before sexual intercourse.
Preporučena doza Fortacin je 3 potiska (3 potiska = 1 doza) na glavić prije spolnog odnosa.
The recommended dose of Gazyvaro in combination with bendamustine is 1,000 mg administered on Day 1 of each 28 day treatment cycle.
Preporučena doza lijeka Gazyvaro u kombinaciji s bendamustinom iznosi 1000 mg, a primjenjuje se dan svakog ciklusa liječenja u trajanju od 28 dana.
The recommended dose of Gazyvaro in combination with bendamustine is 1,000 mg administered on Day 1, Day 8 and Day 15 of the first 28 day treatment cycle.
Preporučena doza lijeka Gazyvaro u kombinaciji s bendamustinom iznosi 1000 mg, a primjenjuje se dan, 8. dan i 15. dan prvog ciklusa liječenja u trajanju od 28 dana.
The recommended dose of Gazyvaro in combination with bendamustine is shown in Table 4.
Preporučena doza lijeka Gazyvaro u kombinaciji s bendamustinom za bolesnike s FL-om prikazana je u Tablici 4.
The recommended dose of Gazyvaro in combination with chlorambucil is 1,000 mg administered over Day 1 and Day 2, (or Day 1 continued), and on Day 8 and Day 15 of the first 28 day treatment cycle.
Preporučena doza lijeka Gazyvaro u kombinaciji s klorambucilom je 1000 mg, a primjenjuje se tijekom 1. i 2. dana (ili u nastavku 1. dana) te 8. dan i 15. dan prvog ciklusa liječenja u trajanju od 28 dana.
The recommended dose of Gilenya is one 0.5 mg capsule taken orally once daily.
Preporučena doza Gilenye je jedna kapsula od 0,5 mg koja se uzima peroralno jedanput na dan.
The recommended dose of Glivec is 100 mg/day for adult patients with HES/CEL.
Za odrasle bolesnike s HES/KEL-om preporučena doza Gliveca iznosi 100 mg/dan.
The recommended dose of Glivec is 400 mg/day for adult patients with MDS/MPD.
Za odrasle bolesnike s MDS/MPD-om preporučena doza Gliveca iznosi 400 mg/dan.
The recommended dose of Glivec is 400 mg/day for adult patients with unresectable and/or metastatic malignant GIST.
Za bolesnike s inoperabilnim i/ili metastazirajućim malignim GIST-om preporučena doza Gliveca iznosi 400 mg/dan.
The recommended dose of Glivec is 800 mg/day for adult patients with DFSP.
Za odrasle bolesnike s DFSP-om preporučena doza Gliveca iznosi 800 mg/dan.
The recommended dose of Glubrava is 30 mg/day pioglitazone plus 1700 mg/day of metformin hydrochloride (this dose is achievable with one tablet of Glubrava 15 mg/850 mg, taken twice a day).
Preporučena doza lijeka Glubrava je 30 mg pioglitazona na dan plus 1700 mg metforminklorida na dan (ova se doza može postići jednom tabletom lijeka Glubrava 15 mg/850 mg, koja se uzima dvaput na dan).
The recommended dose of Harvoni is one tablet once daily with or without food (see section 5.2).
Preporučena doza lijeka Harvoni je jedna tableta jedanput na dan s hranom ili bez nje (vidjeti dio 5.2).
The recommended dose of heparin is 5000 I.U. given as a bolus injection prior to reteplase therapy followed by an infusion of 1000 I.U. per hour starting after the second reteplase bolus.
Preporučena doza heparina iznosi 5000 IU, primijenjena kao bolusna injekcija prije reteplaze, nakon koje slijedi infuzija od 1000 IU po satu koja započinje nakon drugog bolusa reteplaze.
The recommended dose of heparin is 5000 I.U. given as a single injection before Rapilysin, followed by an infusion of 1000 I.U. per hour starting after the second Rapilysin injection.
Preporučena doza heparina iznosi 5000 IU, primijenjena kao jednokratna injekcija prije lijeka Rapilysin, nakon koje slijedi infuzija od 1000 IU po satu koja započinje nakon druge injekcije lijeka Rapilysin.
The recommended dose of Holoclar is 79,000 - 316,000 cells/cm², corresponding to 1 cm² of product/cm² of defect.
Preporučena doza Holoclara je 79 000 – 316 000 stanica/cm², što odgovara 1 cm² lijeka/cm² oštećenja.
The recommended dose of Humira for patients aged 4 to 17 years with plaque psoriasis depends on the weight of your child.
Preporučena doza lijeka Humira za bolesnike u dobi od 4 do 17 godina oboljele od plak psorijaze ovisi o djetetovoj tjelesnoj težini.
The recommended dose of Humira for patients with ankylosing spondylitis axial spondyloarthritis without radiographic evidence of AS and for patients with psoriatic arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection.
U bolesnika s ankilozantnim spondilitisom, aksijalnim spondiloartritisom bez radiološkog dokaza AS- a te u bolesnika sa psorijatičnim artritisom preporučena doza adalimumaba iznosi 40 mg, a daje se kao jednokratna doza svaka dva tjedna supkutanom injekcijom.
The recommended dose of Humira for patients with ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of AS and for patients with psoriatic arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection.
U bolesnika s ankilozantnim spondilitisom, aksijalnim spondiloartritisom bez radiološkog dokaza AS- a te u bolesnika sa psorijatičnim artritisom preporučena doza adalimumaba iznosi 40 mg, a daje se kao jednokratna doza svaka dva tjedna supkutanom injekcijom.
The recommended dose of Humira for patients with enthesitis-related arthritis 6 years of age and older is 24 mg/m² body surface area up to a maximum single dose of 40 mg adalimumab administered every other week via subcutaneous injection.
Preporučena doza lijeka Humira za bolesnike s artritisom povezanim s entezitisom u dobi od 6 godina i starije je 24 mg/m² tjelesne površine do maksimalne pojedinačne doze od 40 mg adalimumaba primijenjene svaki drugi tjedan supkutanom injekcijom.
The recommended dose of Humira for patients with enthesitis-related arthritis, aged 6 to 17 years depends on the height and weight of the child.
Preporučena doza lijeka Humira za bolesnike s artritisom povezanim s entezitisom u dobi od 6 do 17 godina ovisi o visini i težini djeteta.
The recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis, aged 13 to 17 years, is 40 mg every other week.
Preporučena doza lijeka Humira za bolesnike s poliartikularnim juvenilnim idiopatskim artritisom u dobi od 13 do 17 godina je 40 mg svaki drugi tjedan.
The recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis, aged 13 to 17 years, is 40mg every other week.
Preporučena doza lijeka Humira za bolesnike s poliartikularnim juvenilnim idiopatskim artritisom u dobi od 13 do 17 godina je 40 mg svaki drugi tjedan.
The recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis, aged 2 - 12 years, is 24 mg/m² body surface area up to a maximum single dose of 20 mg adalimumab (for patients aged 2 - < 4) and up to a maximum single dose of 40 mg adalimumab (for patients aged 4-12) administered every other week via subcutaneous injection.
Preporučena doza lijeka Humira za bolesnike s poliartikularnim juvenilnim idiopatskim artritisom u dobi 2-12 godina je 24 mg/m² tjelesne površine do maksimalne pojedinačne doze od 20 mg adalimumaba (za bolesnike u dobi od 2 do manje od 4 godine) i do maksimalne pojedinačne doze od 40 mg adalimumaba (za bolesnike u dobi od 4 do 12 godina) primijenjene svaki drugi tjedan supkutanom injekcijom.
The recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis, aged 2 - 12 years, is 24 mg/m² body surface area up to a maximum single dose of 20 mg adalimumab (for patients aged 2-<4) and up to a maximum single dose of 40 mg adalimumab (for patients aged 4-12) administered every other week via subcutaneous injection.
Preporučena doza lijeka Humira za bolesnike s poliartikularnim juvenilnim idiopatskim artritisom u dobi 2-12 godina je 24 mg/m² tjelesne površine do maksimalne pojedinačne doze od 20 mg adalimumaba (za bolesnike u dobi od 2 do manje od 4 godine) i do maksimalne pojedinačne doze od 40 mg adalimumaba (za bolesnike u dobi od 4 do 12 godina) primijenjene svaki drugi tjedan supkutanom injekcijom.
The recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis, aged 2 to 12 years depends on the height and weight of the child.
Preporučena doza lijeka Humira za bolesnike s poliartikularnim juvenilnim idiopatskim artritisom u dobi od 2 do 12 godina ovisi o visini i težini djeteta.
The recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis, aged 2 to 12 years depends on the height and weight of your child.
Preporučena doza lijeka Humira za bolesnike s poliartikularnim juvenilnim idiopatskim artritisom u dobi od 2 do 12 godina ovisi o visini i težini djeteta.
The recommended dose of Humira for patients with polyarticular juvenile idiopathic arthritis, aged 2- 12 years, is 24 mg/m² body surface area up to a maximum single dose of 20 mg adalimumab (for patients aged 2-<4) and up to a maximum single dose of 40 mg adalimumab (for patients aged 4-12) administered every other week via subcutaneous injection.
Preporučena doza lijeka Humira za bolesnike s poliartikularnim juvenilnim idiopatskim artritisom u dobi 2-12 godina je 24 mg/m² tjelesne površine do maksimalne pojedinačne doze od 20 mg adalimumaba (za bolesnike u dobi od 2 do manje od 4 godine) i do maksimalne pojedinačne doze od 40 mg adalimumaba (za bolesnike u dobi od 4 do 12 godina) primijenjene svaki drugi tjedan supkutanom injekcijom.
The recommended dose of HYCAMTIN capsules is 2.3 mg/m2 body surface area/day administered for five consecutive days with a three week interval between the start of each course.
Preporučena doza HYCAMTIN kapsula je 2,3 mg/m2 tjelesne površine/dan, primijenjena tijekom pet uzastopnih dana, s intervalom od tri tjedna između početka svakog ciklusa.
The recommended dose of ibandronic acid is 3 mg, administered as an intravenous injection over 15 - 30 seconds, every three months.
Preporučena doza ibandronatne kiseline iznosi 3 mg, primijenjena putem intravenske injekcije u trajanju od 15 do 30 sekundi svaka tri mjeseca.
The recommended dose of Ilaris for adult patients with gouty arthritis is 150 mg administered subcutaneously as a single dose during an attack.
Preporučena doza Ilarisa za odrasle bolesnike s uričnim artritisom je 150 mg i primjenjuje se supkutano kao jednokratna doza tijekom napada.
The recommended dose of Imatinib Accord is 100 mg/day for patients with HES/CEL.
Za odrasle bolesnike s HES/KEL-om preporučena doza Imatinib Accorda iznosi 100 mg/dan.
The recommended dose of Imatinib Accord is 400 mg/day for patients with MDS/MPD.
Za odrasle bolesnike s MDS/MPD-om preporučena doza Imatinib Accorda iznosi 400 mg/dan.
The recommended dose of imatinib is 100 mg/day for adult patients with HES/CEL.
Za odrasle bolesnike s HES/KEL-om preporučena doza imatiniba iznosi 100 mg/dan.
The recommended dose of imatinib is 400 mg/day for adult patients with MDS/MPD.
Za odrasle bolesnike s MDS/MPD-om preporučena doza imatiniba iznosi 400 mg/dan.
The recommended dose of Imatinib is 600 mg/day for adult patients in blast crisis.
Za odrasle bolesnike u blastičnoj krizi preporučena doza Imatinib iznosi 600 mg/dan.
The recommended dose of Imatinib is 600 mg/day for patients with Ph+ ALL.
Za odrasle bolesnike s Ph+ ALL-om preporučena doza imatiniba iznosi 600 mg/dan.
The recommended dose of imatinib is 800 mg/day for adult patients with DFSP.
Za odrasle bolesnike s DFSP-om preporučena doza imatiniba iznosi 800 mg/dan.
The recommended dose of imatinib is 800 mg/day for patients with DFSP.
Za bolesnike s DFSP-om preporučena doza imatiniba iznosi 800 mg/dan.
The recommended dose of Imatinib is800 mg/day for patients with DFSP.
Za bolesnike DFSP-om preporučena doza imatiniba iznosi 800 mg/dan.
The recommended dose of Imatinib is800 mg/day for patients with DFSP.
Za bolesnike DFSP-om preporučena doza imatinibaiznosi 800 mg/dan.
The recommended dose of Imatinib Teva is 100 mg/day for adult patients with HES/CEL.
Za odrasle bolesnike s HES/KEL-om preporučena doza Imatiniba Teva iznosi 100 mg/dan.
The recommended dose of Imatinib Teva is 400 mg/day for adult patients with MDS/MPD.
Za odrasle bolesnike s MDS/MPD-om preporučena doza Imatiniba Teva iznosi 400 mg/dan.
The recommended dose of Imatinib Teva is 800 mg/day for adult patients with DFSP.
Za odrasle bolesnike s DFSP-om preporučena doza Imatinib Teva iznosi 800 mg/dan.
The recommended dose of Imatinib Teva is 800 mg/day for adult patients with DFSP.
Za odrasle bolesnike s DFSP-om preporučena doza Imatiniba Teva iznosi 800 mg/dan.
The recommended dose of IMBRUVICA is three capsules (420 mg) once a day.
Preporučena doza lijeka IMBRUVICA je tri kapsule (420 mg) jedanput na dan.
The recommended dose of Imnovid is 4 mg per day.
Preporučena doza lijeka Imnovid iznosi 4 mg na dan.
The recommended dose of indinavir is 800 mg orally every 8 hours.
Preporučena doza indinavira je 800 mg peroralno svakih 8 sati.
The recommended dose of INTELENCE for adults is 200 mg (one 200 mg tablet) taken orally twice daily (b.i.d.), following a meal (see section 5.2).
Preporučena doza INTELENCEa za odrasle je 200 mg (jedna tableta od 200 mg), peroralno, dva puta dnevno (b.i.d.) nakon obroka (vidjeti dio 5.2).
The recommended dose of INTELENCE for adults is 200 mg (two 100 mg tablets) taken orally twice daily (b.i.d.), following a meal (see section 5.2).
Preporučena doza INTELENCEa za odrasle je 200 mg (dvije tablete od 100 mg), peroralno, dva puta dnevno (b.i.d.) nakon obroka (vidjeti dio 5.2).
The recommended dose of INTELENCE for paediatric patients (6 years to less than 18 years of age and weighing at least 16 kg) is based on body weight (see table below).
Preporučena doza INTELENCEa za pedijatrijske bolesnike (u dobi od 6 godina do manje od 18 godina i težine najmanje 16 kg) temeljeno je na tjelesnoj težini (vidjeti tablicu ispod).
The recommended dose of INTELENCE is one tablet twice a day.
Preporučena doza INTELENCEa je jedna tableta dva puta dnevno.
The recommended dose of INTELENCE is two tablets twice a day.
Preporučena doza INTELENCEa su dvije tablete dva puta dnevno.
The recommended dose of IntronA is 4 to 5 million IU/m2 administered daily subcutaneously.
Preporučena doza lijeka IntronA je 4 do 5 milijuna IU/m2 primijenjena supkutano svakoga dana.
The recommended dose of INVANZ should be administered, except in cases of severe renal impairment (see Renal impairment).
Treba primijeniti preporučenu dozu lijeka INVANZ, osim u slučajevima teškog oštećenja bubrega (vidjeti Oštećenje funkcije bubrega).
The recommended dose of Invirase is 1000 mg (5 x 200 mg capsules) two times daily with ritonavir 100 mg two times daily in combination with other antiretroviral agents.
Preporučena doza lijeka Invirase je 1000 mg (5 x 200 mg kapsule) dvaput na dan uz ritonavir u dozi od 100 mg dvaput na dan, u kombinaciji s drugim antiretrovirusnim lijekovima.
The recommended dose of Irbesartan Hydrochlorothiazide Zentiva is one tablet a day.
Uobičajena doza lijeka Irbesartan Hydrochlorothiazide Zentiva je jedna ili dvije tablete na dan.
The recommended dose of Irbesartan/Hydrochlorothiazide Teva is one or two tablets a day.
Preporučena doza lijeka Irbesartan/Hidroklorotiazid Teva je jedna ili dvije tablete na dan.
The recommended dose of Irbesartan/Hydrochlorothiazide Teva is one tablet a day.
Preporučena doza lijeka Irbesartan/Hidroklorotiazid Teva je jedna tableta na dan.
The recommended dose of IVEMEND is 150 mg fosaprepitant on Day 1 (day of chemotherapy).
Preporučena doza lijeka IVEMEND je 150 mg fosaprepitanta 1. dana kemoterapije.
The recommended dose of Kalydeco tablets is 150 mg taken orally every 12 hours (300 mg total daily dose) with fat-containing food.
Preporučena doza Kalydeco tableta iznosi 150 mg i uzima se peroralno svakih 12 sati (ukupna dnevna doza je 300 mg) s hranom koja sadrži masti.
The recommended dose of Karvezide is one tablet a day.
Uobičajena doza lijeka Karvezide je jedna ili dvije tablete na dan.
The recommended dose of Kengrexal for patients undergoing PCI is a 30 micrograms/kg intravenous bolus followed immediately by 4 micrograms/kg/min intravenous infusion.
Preporučena doza lijeka Kengrexal za bolesnike koji se podvrgavaju PCI je intravenski bolus od 30 mikrograma/kg nakon kojeg odmah slijedi intravenska infuzija u dozi od 4 mikrograma/kg/min.
The recommended dose of KEYTRUDA is 2 mg/kg administered intravenously over 30 minutes every 3 weeks.
Preporučena doza lijeka KEYTRUDA je 2 mg/kg, primijenjeno intravenski tijekom 30 minuta svaka 3 tjedna.
The recommended dose of Kinzalkomb is one tablet a day.
Preporučena doza Kinzalkomba je jedna tableta dnevno.
The recommended dose of Kinzalmono is one tablet a day.
Preporučena doza Kinzalmonoa je jedna tableta dnevno.
The recommended dose of LEMTRADA is 12 mg/day administered by intravenous infusion for 2 treatment courses.
Preporučena doza lijeka LEMTRADA je 12 mg/dan, a primjenjuje se intravenskom infuzijom u 2 ciklusa liječenja.
The recommended dose of lenalidomide for patients suffering from moderate renal impairment is 10 mg once daily.
Preporučena doza lenalidomida za bolesnike s umjerenim oštećenjem funkcije bubrega iznosi 10 mg jednom dnevno.
The recommended dose of LENVIMA is usually 24 mg once a day (2 capsules of 10 mg and 1 capsule of 4 mg).
Preporučena doza LENVIME je obično 24 mg jedanput na dan (2 kapsule od 10 mg i 1 kapsula od 4 mg).
The recommended dose of Lynparza is 400 mg (eight capsules) taken twice a day.
Preporučena doza lijeka Lynparza iznosi 400 mg (osam kapsula) koje se uzimaju dva puta na dan.
The recommended dose of MabThera in combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory patients with follicular lymphoma is: 375 mg/m2 body surface area per cycle, for up to 8 cycles.
Preporučena doza lijeka MabThera u kombinaciji s kemoterapijom za uvodno liječenje bolesnika s prethodno neliječenim ili relapsirajućim/refraktornim folikularnim limfomom iznosi 375 mg/m2 površine tijela po ciklusu, tijekom najviše 8 ciklusa.
The recommended dose of MabThera in combination with chemotherapy for induction treatment of previously untreated or relapsed/ refractory patients with follicular lymphoma is: first cycle with MabThera intravenous formulation 375 mg/m2 body surface area, followed by subsequent cycles with MabThera subcutaneous formulation injected at a fixed dose of 1400 mg per cycle for up to 8cycles.
Preporučena doza lijeka MabThera u kombinaciji s kemoterapijom za uvodno liječenje bolesnika s prethodno neliječenim ili relapsirajućim/refraktornim folikularnim limfomom je sljedeća: u prvom ciklusu primjenjuje se formulacija lijeka MabThera za intravensku primjenu u dozi od 375 mg/m2 površine tijela, a zatim se u sljedećim ciklusima injicira formulacija lijeka MabThera za supkutanu primjenu u fiksnoj dozi od 1400 mg po ciklusu, tijekom najviše 8 ciklusa.
The recommended dose of MabThera monotherapy used as induction treatment for adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy is: 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for four weeks.
Preporučena doza lijeka MabThera u monoterapiji kod početnog liječenja odraslih bolesnika oboljelih od folikularnog limfoma stadija III-IV koji su rezistentni na kemoterapiju ili su u drugom odnosno sljedećem relapsu nakon kemoterapije iznosi 375 mg/m2 površine tijela, a primjenjuje se u obliku intravenske infuzije jedanput tjedno tijekom četiri tjedna.
The recommended dose of MabThera subcutaneous formulation used as a maintenance treatment for patients with previously untreated follicular lymphoma who have responded to induction treatment is: 1400 mg once every 2 months (starting 2 months after the last dose of induction therapy) until disease progression or for a maximum period of two years.
Preporučena doza lijeka MabThera u formulaciji za supkutanu primjenu u terapiji održavanja u bolesnika s prethodno neliječenim folikularnim limfomom koji su odgovorili na uvodno liječenje iznosi: 1400 mg jedanput svaka 2 mjeseca (počevši 2 mjeseca nakon zadnje doze indukcijske terapije) do progresije bolesti ili najdulje dvije godine.
The recommended dose of MabThera subcutaneous formulation used as a maintenance treatment for patients with relapsed/refractory follicular lymphoma who have responded to induction treatment is: 1400 mg once every 3 months (starting 3 months after the last dose of induction therapy) until disease progression or for a maximum period of two years.
Preporučena doza lijeka MabThera u formulaciji za supkutanu primjenu u terapiji održavanja u bolesnika s relapsirajućim/refraktornim folikularnim limfomom koji su odgovorili na uvodno liječenje iznosi 1400 mg jedanput svaka 3 mjeseca (počevši 3 mjeseca nakon zadnje doze indukcijske terapije) do progresije bolesti ili najdulje dvije godine.
The recommended dose of MabThera subcutaneous formulation used for adult patients is a subcutaneous injection at a fixed dose of 1400 mg irrespective of the patient’s body surface area.
Preporučena doza lijeka MabThera u formulaciji za supkutanu primjenu u odraslih bolesnika je jedna supkutana injekcija lijeka u fiksnoj dozi od 1400 mg, neovisno o površini tijela bolesnika.
The recommended dose of MabThera subcutaneous formulation used for adult patients is a subcutaneous injection at a fixed dose of 1600 mg irrespective of the patient’s body surface area.
Preporučena doza lijeka MabThera u formulaciji za supkutanu primjenu u odraslih bolesnika je jedna supkutana injekcija lijeka u fiksnoj dozi od 1600 mg, neovisno o površini tijela bolesnika.